Amgen, Bristol beat the Street in 3Q

A slew of new earnings figures out today, with some drugmakers reporting better-than-expected results, and even upping their 2008 year-end forecasts. Others, namely Eli Lilly, weren't so fortunate: the Indianapolis pharma slipped to a loss on big-time settlements of its Zyprexa legal troubles. Here's a digest:

  • New warnings about Amgen’s blockbuster anemia drug didn’t hit the biotech company as hard as Wall Street had forecast. The company reported Street-beating earnings of $1.2 billion, up from $201 million a year earlier. Now, Amgen predicts full-year EPS to hit $4.45 to $4.55 per share, up from an earlier forecast of $4.25 to $4.45.
  • Bristol-Myers Squibb trumpeted a tripling of third-quarter net to $2.58 billion on the $4.1 billion sale of its high-tech dressing and wound-care business, Conva-Tec. Bristol also reported healthy increases in product sales--14 percent overall--as revenues reached $5.25 billion. The company now expects EPS for the year to hit the upper half of its previous forecast, or $1.65 to $1.70 per share.
  • Eli Lilly swung to a loss, hurt by a previously announced charge to settle two government investigations into its Zyprexa marketing. The company posted a loss of $466 million, or 43 cents a share, compared with $926 million, or 85 cents a share, for the same period in 2007. Excluding certain items, Lilly would have reported 3Q EPS of $1.04 cents this year versus 91 cents last year.
  • Wyeth reported a drop in profits to $1.14 billion, but the company still managed to meet analyst forecasts as it continues with a restructuring program designed to compensate for competition from generics. A lackluster debut for Pristiq, an antidepressant-slash-menopausal medication, didn't help matters.

- see Amgen's numbers
- check out Bristol's results
- read about Wyeth earnings
- review Eli Lilly's report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.